Cogent Biosciences (NASDAQ:COGT) Stock Falls 4.5% - Time to Sell?

Key Points

• Cogent Biosciences shares fell 4.5% to $30.23 in Wednesday mid-day trading, while volume was 90% below its average.
• The company reported a quarterly loss of $0.59 per share, missing analysts’ expected loss of $0.56.
• Analyst views remain mostly positive: the consensus is “Moderate Buy” with a $53.57 average price target, though one analyst rates the stock a Sell. HC Wainwright maintained a Buy rating and raised its target to $56, while its earnings estimates showed both improvements and near-term reductions.

Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) shares traded down 4.5% during mid-day trading on Wednesday. The stock traded as low as $30.98 and last traded at $30.2250. 208,606 shares were traded during trading, a decline of 90% from the average session volume of 2,157,045 shares. The stock had previously closed at $31.64.

Cogent Biosciences News Summary

These are some of the COGT news items that stood out recently:

• Positive Sentiment: HC Wainwright raised its FY2027 EPS estimate to a loss of $1.09 from $1.28 and lifted its Q3 2027 forecast from a loss to a profit of $0.19 per share. It also narrowed projected losses for Q2 and Q4 2027. The firm maintained its Buy rating and $56 price target, supporting a more optimistic longer-term outlook. HC Wainwright forecast article
• Neutral Sentiment: A separate report said COGT had moved above its 50-day moving average after its earnings release. That technical signal may indicate improving momentum, though it differs from the supplied snapshot, which places the shares below that average. Moving-average article
• Negative Sentiment: HC Wainwright lowered its Q4 2026 EPS estimate to a loss of $0.67 from $0.62 and its Q1 2027 estimate to a loss of $0.51 from $0.50, tempering the longer-term improvement. Cogent also recently reported a quarterly loss per share wider than analysts expected, adding near-term pressure.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Cogent Biosciences in a research report on Friday, October 2nd. Guggenheim raised their price objective on shares of Cogent Biosciences from $45.00 to $52.00 and gave the company a "buy" rating in a research note on Wednesday, August 12th. Wedbush reissued an "outperform" rating and set a $55.00 target price on shares of Cogent Biosciences in a report on Wednesday, September 16th. Piper Sandler increased their price target on Cogent Biosciences from $52.00 to $55.00 and gave the company an "overweight" rating in a research note on Monday, August 17th. Finally, HC Wainwright lifted their price target on Cogent Biosciences from $55.00 to $56.00 and gave the company a "buy" rating in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $53.57.

Cogent Biosciences Stock Performance

The firm's 50-day simple moving average is $31.74 and its two-hundred day simple moving average is $35.44. The company has a current ratio of 10.99, a quick ratio of 13.57 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $5.13 billion, a PE ratio of -13.16 and a beta of 0.36.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The technology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.03). On average, equities research analysts expect that Cogent Biosciences, Inc. will post -2.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cogent Biosciences

Hedge funds have recently made changes to their positions in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Cogent Biosciences by 26.5% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 209,402 shares of the technology company's stock valued at $8,104,000 after acquiring an additional 43,892 shares during the period. Sculptor Capital LP bought a new position in Cogent Biosciences during the second quarter worth about $1,935,000. Wellington Management Group LLP lifted its stake in Cogent Biosciences by 21.4% during the second quarter. Wellington Management Group LLP now owns 4,343,977 shares of the technology company's stock worth $168,112,000 after purchasing an additional 765,355 shares during the period. Legal & General Group Plc acquired a new stake in Cogent Biosciences during the second quarter valued at approximately $3,824,000. Finally, SEB Asset Management AB acquired a new stake in Cogent Biosciences during the first quarter valued at approximately $6,329,000.

Cogent Biosciences Company Profile

Cogent Biosciences is a clinical-stage biotechnology company developing precision medicines for diseases driven by specific genetic mutations. Its research focuses on targeted therapies intended to address the underlying causes of these conditions. The company's lead investigational medicine, bezuclastinib, is a selective inhibitor of the KIT protein. Cogent has studied it in clinical programs for systemic mastocytosis and gastrointestinal stromal tumors (GIST), conditions in which abnormal KIT signaling can play a role.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.